We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+2.72%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.67B
AUM Growth
+$920K
Cap. Flow
+$82.4M
Cap. Flow %
3.09%
Top 10 Hldgs %
54.57%
Holding
76
New
9
Increased
18
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
GHRS icon
GH Research
GHRS
+$189M
2
ARGX icon
argenx
ARGX
+$97.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$42.5M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$34.1M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$29.8M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$239M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$61.3M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$61.3M
4
CTMX icon
CytomX Therapeutics
CTMX
+$43.1M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$1.95B
$202M 7.55%
+9,275,156
New +$189M
ARGX icon
2
argenx
ARGX
$54.6B
$196M 7.35%
651,204
+341,605
+110% +$97.1M
OLMA icon
3
Olema Pharmaceuticals
OLMA
$1.03B
$186M 6.99%
6,661,503
– –
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.92B
$168M 6.31%
3,754,095
-205,356
-5% -$6.78M
MRUS
5
DELISTED
Merus
MRUS
$153M 5.75%
7,285,071
– –
KYMR icon
6
Kymera Therapeutics
KYMR
$8.8B
$128M 4.78%
2,630,658
– –
XOMA
7
DELISTED
Xoma
XOMA
$120M 4.5%
3,530,543
– –
RPTX
8
DELISTED
Repare Therapeutics
RPTX
$116M 4.35%
3,722,398
– –
RLAY icon
9
Relay Therapeutics
RLAY
$4.24B
$108M 4.03%
2,938,202
+65,055
+2% +$2.14M
RVMD icon
10
Revolution Medicines
RVMD
$40.9B
$78.9M 2.96%
2,485,049
-458,000
-16% -$16M
RCUS icon
11
Arcus Biosciences
RCUS
$3.55B
$76.8M 2.88%
2,797,822
+921,700
+49% +$26.3M
EPIX
12
DELISTED
ESSA Pharma
EPIX
$70M 2.63%
2,451,561
-456,765
-16% -$13.3M
ACIU icon
13
AC Immune
ACIU
$241M
$67.8M 2.54%
8,545,179
+1,040,600
+14% +$7.19M
FDMT icon
14
4D Molecular Therapeutics
FDMT
$526M
$48.3M 1.81%
2,005,862
+974,792
+95% +$29.8M
VSTM icon
15
Verastem
VSTM
$536M
$45.9M 1.72%
940,522
-16,228
-2% -$677K
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.73B
$42.7M 1.6%
2,486,429
+2,322,905
+1,421% +$42.5M
LXRX icon
17
Lexicon Pharmaceuticals
LXRX
$1.04B
$38.5M 1.44%
8,394,000
– –
REPL icon
18
Replimune Group
REPL
$35.3M 1.32%
918,928
+457,500
+99% +$15.6M
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$35.1M 1.32%
3,094,174
– –
KURA icon
20
Kura Oncology
KURA
$826M
$34.1M 1.28%
1,635,112
– –
RAIN
21
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$30.2M 1.13%
+1,945,949
New +$34.1M
SPRO icon
22
Spero Therapeutics
SPRO
$69.5M
$29.8M 1.12%
2,137,978
– –
JANX icon
23
Janux Therapeutics
JANX
$950M
$29.4M 1.1%
+1,176,681
New +$26.2M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.2B
$29.3M 1.1%
1,571,778
-1,910,000
-55% -$35.2M
PNT
25
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$28.5M 1.07%
2,772,226
+2,000,000
+259% +$20.3M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2021 Portfolio in Review

As of Q2 2021, BVF Inc held 76 positions worth $2.67B, up 0.03% from $2.67B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

BVF Inc deployed $82.4M of net new capital in Q2 2021, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was GH Research: 9,275,156 shares worth $202M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $35.2M trimmed.

  • BVF Inc's largest Q2 2021 buy was GH Research: 9,275,156 shares worth $202M.
  • BVF Inc added most to argenx in Q2 2021, an estimated $97.1M increase.
  • BVF Inc's biggest Q2 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $35.2M.
  • BVF Inc fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $239M.
  • BVF Inc's ten largest holdings make up 55% of its $2.67B portfolio in Q2 2021.
  • BVF Inc opened 9 new positions and closed 6 in Q2 2021.
  • BVF Inc's portfolio value rose 0.03% quarter-over-quarter to $2.67B.

Based on BVF Inc's 13F filing for Q2 2021, filed 16 Aug 2021.